Skip to content

Quercetin Phytosome® Chronic Fatigue Symptoms

Effectiveness of a 3-months Dietary Supplementation Based on Quercetin Phytosome®) for the Treatment of Chronic Fatigue Symptoms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05730660
Enrollment
80
Registered
2023-02-16
Start date
2022-09-01
Completion date
2023-01-31
Last updated
2024-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Composition, Chronic Fatigue Symptoms, Physical Performance, Sleep

Brief summary

The purpose of this study is to evaluate whether a 3-month period of quercetin supplementation (500 mg of Quercetin Phytosome®) is useful in the treatment of chronic fatigue, as assessed by the Fatigue Impact Scale (FIS-40). Secondary end points are sleep assessment through Pittsburgh Sleep Quality Index (PSQI) and muscle performance assessment through the Short Physical Performance Battery (SPPB) and body composition assessment using DXA.

Interventions

DIETARY_SUPPLEMENTQuercetin group

2 capsules a day of Quercetin Fitosoma® of 250 mg each

DIETARY_SUPPLEMENTPlacebo group

2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.

Sponsors

Azienda di Servizi alla Persona di Pavia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥ 18 years old * Chronic fatigue symptoms recorded using a self-reported fatigue score assessed using the validated Fatigue Impact Scale (FIS- 40) that comprised chronic tiredness impacts related to physical, cognitive and psychosocial functions.

Exclusion criteria

* Patients with any active medical condition that explains chronic fatigue (untreated hypothyroidism, sleep apnea, narcolepsy, drug side effects, and iron deficiency anemia) * Previous diagnosis not unequivocally resolved (chronic hepatitis, malignant tumors) * Past neuropsychiatric disorders or current severe depressive disorder with psychotic or melancholy features, bipolar disorder, schizophrenia, delusional disorder, dementia, anorexia nervosa, bulimia nervosa * Participation in another clinical trial of the same or different nature within 30 days prior to inclusion in the study * Failure to provide signed informed consent * Consumption of certain drugs/supplements that could affect outcome measures in the past 90 days or whose discontinuation could be a significant problem * Anticoagulant treatment * Pregnancy or breastfeeding * Smoking, alcohol or substance abuse * Obesity (BMI \> 30 kg/m²)

Design outcomes

Primary

MeasureTime frameDescription
chronic fatigue symptomsAt baseline and after 3 monthsThe primary outcome is the change in self-reported fatigue scores assessed using the Fatigue Impact Scale (FIS-40). The FIS-40 comprises 40 items divided into three domains (cognitive, physical, and psychosocial), each item scored from 0 (no fatigue) to 4 (severe fatigue). The total score ranges from 0 to 160, with higher scores indicating worse fatigue.

Secondary

MeasureTime frameDescription
Sleep qualityAt baseline and after 3 monthsSleep disturbances are assessed using the 19-item self-administered Pittsburgh Sleep Quality Index (PSQI) questionnaire. Scores are obtained on each of the seven sleep quality domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping pills, and daytime dysfunction. Each component is rated from 0 to 3 (0 = no sleep problems and 3 = severe sleep problems). The overall PSQI score ranges from 0 to 21 points, with scores ≥5 indicating worse sleep quality
Physical performanceAt baseline and after 3 monthsPhysical performance is assessed using the Short Physical Performance Battery test
Body compositionAt baseline and after 3 monthsBody composition is assessed using the dual X-Ray absorptiometry (DXA)
Life qualityAt baseline and after 3 monthsQuality of life is assessed using the Short-Form 12-Item Health Survey (SF-12), a short and generic measure of health status that reproduces the 2 summary scores of the SF-36. The summary of the physical component score and the summary score of the mental component, addressing eight health domains (physical functioning, physical role, body pain, general health, vitality, social functioning, emotional role, and mental health). Each domain is scored separately, and the total scores for the physical and mental components range from 0 to 100, with higher scores indicating better health-related quality of life.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026